What Is GLP-1 and Why Does It Matter for Weight Loss?
If you’ve been researching weight loss options in the past few years, you’ve almost certainly come across the term GLP-1. It’s become one of the most discussed topics in medicine — and for good reason.
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in the gut after eating. Its job is to signal to your brain that you’re full, slow the emptying of your stomach, and regulate blood sugar levels by stimulating insulin release. In short, it’s one of your body’s key mechanisms for appetite and metabolic control.
The problem is that many people — particularly those struggling with stubborn weight — don’t produce enough GLP-1, or their body doesn’t respond to it effectively. Hunger signals stay elevated, fullness arrives late, cravings persist, and the cycle of overeating and frustration continues regardless of willpower or effort.
GLP-1 receptor agonists are medications designed to mimic this hormone, essentially restoring the satiety and metabolic signals that many patients are missing. The result isn’t just reduced appetite — it’s a fundamental shift in how the body processes food, manages blood sugar, and stores fat.
Today, two GLP-1 medications dominate the conversation: semaglutide and tirzepatide. Both are clinically proven, both are administered as weekly injections, and both can produce meaningful weight loss results. But they are not the same — and for many patients, the difference matters significantly.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management under the brand name Ozempic. Its weight loss applications were later approved under the brand name Wegovy, making it one of the first GLP-1 medications specifically indicated for chronic weight management in adults.
Semaglutide works by binding to GLP-1 receptors in the brain and gut, suppressing appetite, reducing food intake, and slowing gastric emptying. Clinical trials showed an average body weight reduction of approximately 15% over 68 weeks — a landmark result that shifted how the medical community approaches weight management.
Semaglutide is administered as a once-weekly subcutaneous injection, with dosing gradually increased over several months to improve tolerability and minimize gastrointestinal side effects.
For many patients, semaglutide represented a genuine breakthrough — particularly those for whom diet and exercise alone had repeatedly failed. It remains a widely used and well-studied medication with a strong safety profile.
What Is Tirzepatide — and What Makes It Different?
Tirzepatide is the next generation of weight loss medication, and it works differently from semaglutide in one critical way: it’s a dual agonist.
Where semaglutide targets only the GLP-1 receptor, tirzepatide activates both the GLP-1 receptor and the GIP receptor — GIP standing for glucose-dependent insulinotropic polypeptide, a second metabolic hormone that works alongside GLP-1 to regulate insulin secretion, fat storage, and energy balance.
This dual mechanism is not just an incremental improvement. GIP receptors are found in fat tissue, the brain, and the pancreas, meaning tirzepatide acts on metabolic pathways that semaglutide simply doesn’t reach. The result is a more comprehensive effect on appetite suppression, fat metabolism, and insulin sensitivity.
Tirzepatide was approved by the FDA under the brand name Mounjaro for type 2 diabetes in 2022, and subsequently approved under the name Zepbound specifically for chronic weight management in 2023. Clinical trial data from the SURMOUNT trials showed patients losing an average of 20–22% of their body weight over 72 weeks — results that surpassed everything seen with semaglutide and, in some comparisons, approached outcomes typically associated with bariatric surgery.
Semaglutide vs. Tirzepatide: A Direct Comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Receptor Targets | 1 (GLP-1) | 2 (GLP-1 + GIP) |
| Avg. Weight Loss | ~15% body weight | ~20–22% body weight |
| Administration | Weekly injection | Weekly injection |
| FDA Approval (weight) | Wegovy (2021) | Zepbound (2023) |
| Blood Sugar Control | Strong | Stronger |
| Fat Tissue Impact | Indirect via appetite | Direct via GIP receptors |
| Side Effect Profile | Nausea, GI symptoms | Similar; often better tolerated |
Weight Loss Results
The clinical evidence is clear. Head-to-head trials — most notably the SURMOUNT-5 study published in 2025 — showed that tirzepatide produced significantly greater weight loss than semaglutide in patients with obesity. Participants on tirzepatide lost an average of 47 pounds compared to 25 pounds on semaglutide. That’s not a marginal difference — it’s nearly double the outcome.
Mechanism of Action
Both medications suppress appetite and slow gastric emptying through GLP-1 receptor activation. The key distinction is that tirzepatide’s additional GIP activity creates a synergistic effect — one that more powerfully reduces hunger, enhances fat burning, and improves insulin sensitivity simultaneously. GIP receptors expressed in adipose (fat) tissue play a direct role in how the body stores and mobilizes fat, giving tirzepatide a metabolic advantage that semaglutide simply doesn’t have.
Side Effect Profile
Both medications can cause nausea, vomiting, constipation, or diarrhea — particularly in the early weeks of treatment. These effects are managed through gradual dose escalation and typically resolve as your body adjusts. Many patients report that tirzepatide is better tolerated than semaglutide at comparable doses, a finding echoed in clinical data, though individual responses vary.
Cost and Access
Both medications have faced supply and insurance coverage challenges. Tirzepatide availability has improved significantly and is the medication we currently offer at Lotus MD as part of our physician-supervised medical weight loss program in Roseville.
Why We Recommend Tirzepatide at Lotus MD
At Lotus MD, we don’t offer both medications and let patients guess. After reviewing the clinical evidence and treating patients in our Roseville and Granite Bay practice, we’ve made tirzepatide our primary recommendation for GLP-1 weight loss therapy — and here’s why.
Greater Outcomes for the Same Commitment
Both medications require a weekly injection and the same lifestyle discipline. If the commitment level is identical, we believe patients deserve the medication that delivers the best results. The data is unambiguous — tirzepatide produces substantially greater weight loss.
Dual Metabolic Action
Our philosophy at Lotus MD is rooted in treating root causes, not just symptoms. Weight gain is often driven by a combination of hormonal imbalance, insulin resistance, and metabolic dysfunction. Tirzepatide’s dual GLP-1 and GIP mechanism addresses more of those pathways simultaneously — making it a better fit for our comprehensive, physiology-first approach to weight management.
Better Metabolic Outcomes Beyond the Scale
Tirzepatide’s effects on insulin sensitivity and blood sugar regulation are clinically superior to semaglutide. For patients dealing with prediabetes, metabolic syndrome, or PCOS-related weight gain — conditions we see frequently in our practice — this broader metabolic benefit matters enormously.
Tolerability
Clinical data and our own patient experience suggest tirzepatide is generally well-tolerated, often more so than semaglutide at equivalent stages of treatment. Fewer patients discontinue due to side effects, which means more patients successfully complete their program and reach their goals.
We always conduct a thorough consultation and medical review before recommending any medication. Tirzepatide is not appropriate for everyone, and we take that responsibility seriously. But for the majority of our patients who qualify, it represents the most effective GLP-1 option currently available.
Who Is a Good Candidate for GLP-1 Therapy?
GLP-1 medications like tirzepatide are not a shortcut — they are a clinically validated medical intervention for people whose weight is affecting their health and quality of life.
You May Be a Strong Candidate If You:
- Have a BMI of 27 or higher, especially with a weight-related condition such as high blood pressure, prediabetes, or high cholesterol
- Have struggled to maintain weight loss through diet and exercise alone
- Are dealing with metabolic dysfunction, insulin resistance, or hormone-related weight gain
- Are not pregnant or planning to become pregnant during treatment
- Do not have a personal or family history of medullary thyroid cancer or MEN2 syndrome
- Are committed to a physician-supervised program that includes lifestyle guidance, not just medication
GLP-1 Therapy May Not Be Appropriate If You:
- Have a history of pancreatitis
- Have certain thyroid conditions (discussed in full during your consultation)
- Are currently taking medications with significant interactions
- Are not prepared for the gradual dose escalation and monitoring the program requires
The only way to know with certainty is through a proper consultation and medical review. At Lotus MD, we assess every patient individually — evaluating your health history, current medications, metabolic markers, and goals — before recommending any treatment plan.
What to Expect from GLP-1 Treatment at Lotus MD
Our medical weight loss program is built around physician supervision, not a prescription-and-goodbye model. Here’s what the process looks like.
Initial Consultation
A comprehensive assessment that includes your health history, current medications, metabolic goals, and a review of whether tirzepatide is the right fit. We also use InBody 380S body composition analysis to establish a precise baseline — not just your weight on a scale, but your muscle mass, fat distribution, and metabolic age.
Personalized Treatment Plan
If tirzepatide is appropriate, we build a dosing schedule tailored to you — starting low and increasing gradually to maximize tolerability and results. Your plan includes nutritional guidance, activity recommendations, and sleep and stress optimization strategies, because medication alone only goes so far.
Ongoing Monitoring
Regular check-ins to track progress, adjust dosing, manage any side effects, and keep you accountable. We monitor body composition changes — not just weight — so you can see exactly how your muscle-to-fat ratio is shifting over time.
Long-Term Strategy
Our goal is not to keep you on medication indefinitely. We work with you to build metabolic resilience — the habits, hormonal balance, and lifestyle foundation that sustain your results after the active treatment phase.
Frequently Asked Questions
Is tirzepatide better than semaglutide?
Based on current clinical evidence, tirzepatide produces significantly greater weight loss than semaglutide — approximately 20–22% versus 15% of body weight. Its dual GLP-1 and GIP mechanism also provides broader metabolic benefits. For most patients who qualify, we consider tirzepatide the superior option for GLP-1 weight loss therapy.
How quickly will I lose weight on tirzepatide?
Most patients begin noticing reduced appetite within the first one to two weeks. Measurable weight loss typically becomes evident by week four to eight, with the most significant results building over six to twelve months as the dose is gradually increased. Individual results vary based on starting weight, lifestyle factors, and metabolic health.
What are the side effects of tirzepatide?
The most common side effects are gastrointestinal — nausea, constipation, mild diarrhea, or reduced appetite. These are most pronounced in the early weeks and typically resolve as your body adjusts. Our gradual dose escalation protocol is specifically designed to minimize these effects. Serious side effects are rare but discussed in full during your consultation.
Do I need to stay on tirzepatide forever?
Not necessarily. Some patients use GLP-1 therapy as a tool to achieve significant weight loss and then work with their provider to maintain results through lifestyle changes. Others benefit from ongoing low-dose maintenance. This is a conversation we have with every patient based on their individual goals and health profile.
Can I get tirzepatide in Roseville or Granite Bay?
Yes. Lotus MD offers physician-supervised tirzepatide treatment at our Granite Bay office (Monday–Friday) and Sacramento office (Saturdays). We serve patients throughout the greater Sacramento area including Roseville, Rocklin, Folsom, and Citrus Heights.
How is Lotus MD’s program different from telehealth weight loss services?
Unlike telehealth platforms that provide a prescription with minimal follow-up, our program is fully physician-led and includes InBody 380S body composition analysis, ongoing monitoring, lifestyle coaching, and a long-term strategy. Dr. Sanghera evaluates every patient personally and remains involved throughout the process.
How do I get started?
The first step is a consultation at our Roseville-area office. We’ll assess whether tirzepatide is right for you, answer all your questions, and build a personalized plan tailored to your goals. Visit our medical weight loss page or call us at +1 (916) 249-7903 to book your appointment.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications including tirzepatide are prescription treatments and require a physician evaluation to determine candidacy. Results vary by individual.
